JAK2 and non-small cell lung carcinoma: To determine whether the Jak2/STAT3 signaling pathway is involved in FXR-induced NSCLC migration, invasion, and angiogenesis, stably FXR-overexpressing A549 cells were treated with STAT3 inhibitor stattic or transfected with STAT3-siRNAs.